NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Ltd. (NRSN) priced its initial public offering on Dec 10, 2021 at $6.00 per share, raising $12M, and listed on Nasdaq Capital Market. At the IPO price its market capitalization was about $65.7M. Maxim Group was lead-left underwriter. Covington & Burling advised the company and Goldfarb Gross Seligman and Ellenoff Grossman & Schole advised the underwriters.

NeuroSense Therapeutics Ltd. is a clinical-stage biotechnology company that discovers and develops treatments for debilitating neurodegenerative diseases with limited therapeutic options, including amyotrophic lateral sclerosis (ALS), Alzheimer's disease and Parkinson's disease.

Status

IPO

Ticker

NRSN

Exchange

Nasdaq Capital Market

Priced

Dec 10, 2021

IPO price

$6.00

Raised

$12M

Market cap at IPO price

$65.7M

First filed

Oct 18, 2021

Underwriters

Maxim Group

Company counsel

Covington & Burling

Underwriters' counsel

Goldfarb Gross Seligman and Ellenoff Grossman & Schole

Sector

Biotech & pharma

Country / state

Israel

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.